190 related articles for article (PubMed ID: 37282600)
1. Determination of potential combination of non-β-lactam, β-lactam, and β-lactamase inhibitors/β-lactam enhancer against class D oxacillinases producing Acinetobacter baumannii: Evidence from in-vitro, molecular docking and dynamics simulation.
Gopikrishnan M; Ramireddy S; Varghese RP; Bakathavatchalam YD; D TK; Manesh A; Walia K; Veeraraghavan B; C GPD
J Cell Biochem; 2023 Jul; 124(7):974-988. PubMed ID: 37282600
[TBL] [Abstract][Full Text] [Related]
2. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
3. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
4.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
5.
Santerre Henriksen A; Jeannot K; Oliver A; Perry JD; Pletz MW; Stefani S; Morrissey I; Longshaw C;
Microbiol Spectr; 2024 Apr; 12(4):e0383623. PubMed ID: 38483164
[TBL] [Abstract][Full Text] [Related]
6. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020.
Liu PY; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Lee YL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
J Microbiol Immunol Infect; 2022 Oct; 55(5):888-895. PubMed ID: 34521591
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
9. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant
Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044
[TBL] [Abstract][Full Text] [Related]
10.
Bakthavatchalam YD; Elangovan D; Jaganathan SV; Subburaju N; Shankar A; Manokaran Y; J S; Devi R; Baveja S; Devi S; S J; Bhattacharya S; S M R; Yesudhason B; Shetty V; Mutreja A; Manesh A; Varghese GM; Marwick CA; Parcell BJ; Gilbert IH; Veeraraghavan B
Microbiol Spectr; 2023 Feb; 11(2):e0492522. PubMed ID: 36847537
[TBL] [Abstract][Full Text] [Related]
11.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
12. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
13.
Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
[TBL] [Abstract][Full Text] [Related]
14. C6 Hydroxymethyl-Substituted Carbapenem MA-1-206 Inhibits the Major
Stewart NK; Toth M; Alqurafi MA; Chai W; Nguyen TQ; Quan P; Lee M; Buynak JD; Smith CA; Vakulenko SB
mBio; 2022 Jun; 13(3):e0036722. PubMed ID: 35420470
[TBL] [Abstract][Full Text] [Related]
15. The Novel β-Lactam Enhancer Zidebactam Augments the
Bhagwat SS; Periasamy H; Takalkar SS; Palwe SR; Khande HN; Patel MV
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670419
[TBL] [Abstract][Full Text] [Related]
16. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
Jean SS; Gould IM; Lee WS; Hsueh PR;
Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
18. Targeting Multidrug-Resistant
Barnes MD; Kumar V; Bethel CR; Moussa SH; O'Donnell J; Rutter JD; Good CE; Hujer KM; Hujer AM; Marshall SH; Kreiswirth BN; Richter SS; Rather PN; Jacobs MR; Papp-Wallace KM; van den Akker F; Bonomo RA
mBio; 2019 Mar; 10(2):. PubMed ID: 30862744
[TBL] [Abstract][Full Text] [Related]
19. The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli.
Roach EJ; Uehara T; Daigle DM; Six DA; Khursigara CM
Microbiol Spectr; 2021 Oct; 9(2):e0091821. PubMed ID: 34494877
[TBL] [Abstract][Full Text] [Related]
20. Multicenter surveillance of
Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
